Assembly Biosciences (NASDAQ:ASMB) released its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Bloomberg Earnings reports. Assembly Biosciences had a negative return on equity of 56.56% and a negative net margin of 379.22%. The firm had revenue of $3.57 million during the quarter, compared to the consensus estimate of $1.88 million.
NASDAQ:ASMB opened at $42.11 on Tuesday. Assembly Biosciences has a 52 week low of $40.71 and a 52 week high of $42.04.
Several research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 10th. ValuEngine upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. BidaskClub downgraded shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, April 18th. B. Riley lowered their price objective on shares of Assembly Biosciences to $45.00 and set a “neutral” rating for the company in a research note on Tuesday, May 8th. Finally, Jefferies Group increased their price target on shares of Assembly Biosciences to $75.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Assembly Biosciences presently has an average rating of “Hold” and an average price target of $60.50.
In related news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $56.37, for a total value of $56,370.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 3,000 shares of company stock worth $148,750 in the last 90 days. 18.20% of the stock is currently owned by corporate insiders.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.